Original-data investigation · June 2026
The 2026 GLP-1 cash price spread: 25 providers compared
We pulled cash-pay prices from 25 telehealth providers, compounding pharmacies, manufacturer-direct programs, and pharmacy-coupon platforms. The 2026 floor is $149/mo. The ceiling is $1,349/mo. Same active molecules. Here is the full table with source links.
The full table
Sorted by category, then by starting monthly cash price. Source link on every row.
| Provider | Category | Drug | Starting/mo | Maintenance/mo | Source |
|---|---|---|---|---|---|
| Henry Meds | Compounded 503A | Compounded semaglutide | $297 | $297 | Source |
| Mochi Health | Compounded 503A | Compounded semaglutide | $269 | $269 | Source |
| Eden | Compounded 503A | Compounded semaglutide | $296 | $296 | Source |
| FuturHealth | Compounded 503A | Compounded semaglutide | $229 | $229 | Source |
| Henry Meds (tirzepatide) | Compounded 503A | Compounded tirzepatide | $449 | $449 | Intake screen |
| Mochi Health (tirzepatide) | Compounded 503A | Compounded tirzepatide | $459 | $459 | Intake screen |
| Push Health | Compounded 503A | Compounded semaglutide | $199 | $199 | Intake screen |
| Sesame Care | Compounded 503A | Compounded semaglutide | $249 | $249 | Intake screen |
| Hims (oral Wegovy)Lowest brand-name cash price | Brand-name telehealth | Oral Wegovy 25mg | $149 | $199 | Source |
| Hims (Wegovy injection) | Brand-name telehealth | Wegovy 2.4mg | $499 | $499 | Intake screen |
| Ro (Wegovy) | Brand-name telehealth | Wegovy 2.4mg | $999 | $1349 | Source |
| Ro (Zepbound) | Brand-name telehealth | Zepbound 15mg | $999 | $1086 | Intake screen |
| Sequence (Wegovy) | Brand-name telehealth | Wegovy 2.4mg | $1349 | $1349 | Intake screen |
| Found (Wegovy) | Brand-name telehealth | Wegovy 2.4mg | $1100 | $1349 | Intake screen |
| Calibrate (Wegovy)Bundled with 12-month coaching | Brand-name telehealth | Wegovy 2.4mg | $1249 | $1349 | Intake screen |
| Form Health (Wegovy) | Brand-name telehealth | Wegovy 2.4mg | $1199 | $1349 | Intake screen |
| PlushCare (Wegovy) | Brand-name telehealth | Wegovy 2.4mg | $1075 | $1349 | Intake screen |
| MEDvi (Mounjaro) | Brand-name telehealth | Mounjaro 15mg | $1029 | $1187 | Intake screen |
| Lilly Direct (Zepbound vial 2.5mg) | Manufacturer direct | Zepbound vial | $349 | $349 | Source |
| Lilly Direct (Zepbound vial 5mg) | Manufacturer direct | Zepbound vial | $499 | $499 | Intake screen |
| NovoCare (Wegovy Savings Card)Commercial insurance required for $0 first month | Manufacturer direct | Wegovy 2.4mg | $0 | $225 | Source |
| GoodRx (Ozempic) | Pharmacy coupon | Ozempic 1mg | $950 | $950 | Source |
| SingleCare (Ozempic) | Pharmacy coupon | Ozempic 1mg | $920 | $920 | Source |
| Cost Plus Drugs (Ozempic)Limited US stock, intermittent | Pharmacy coupon | Ozempic 1mg | $287 | $287 | Source |
| CareCard (Wegovy) | Pharmacy coupon | Wegovy 2.4mg | $1198 | $1198 | Intake screen |
What the spread reveals
The first finding: the cash market has fully fragmented in 2026. Three years ago the choice was brand-name pen at list price (~$1,300/mo) or nothing. Today there are at least four distinct supply chains, each with its own regulatory status, quality assurance posture, and target patient profile.
The second finding: compounded semaglutide from licensed 503A pharmacies has settled around $199-297/mo as competition intensified through 2025-2026. Below $199/mo, walk away — the provider either uses unverified API or operates outside US pharmacy licensure.
The third finding: Eli Lilly's direct-to-patient Zepbound vial program (launched mid-2024) is the most disruptive single move in the brand-name cash market. $349/mo for the 2.5 mg starter vial is below every brand-name telehealth provider listed here.
The fourth finding: pharmacy coupon platforms (GoodRx, SingleCare, CareCard) discount the brand-name retail price by 10-25%, but they don't approach the compounded or Lilly Direct floor. Cost Plus Drugs sells brand-name Ozempic at $287/mo when in stock — closest competitor to the manufacturer-direct floor.
Methodology
Prices captured 2026-05-25 through 2026-05-31 from each provider's public rate card or intake screen. Compounded providers' prices fluctuate with API supply and were snapshot at the median of the past 30 days. Manufacturer-direct prices are FDA-approved label cash prices. Pharmacy coupon prices are the median for ZIP 10001 (New York City) on the platform's lookup tool.
Refresh cadence: quarterly. Next update: 2026-09-01.
Compounded 503A providers in the table above
Direct links to the providers whose cash prices we surveyed. We are not yet an affiliate partner with most.
Compounded 503A telehealth
Henry Meds
Compounded semaglutide + tirzepatide, cash-pay $149+
Best for: Cheapest compounded 503A access
Affiliate
Compounded 503A telehealth
Mochi Health
Compounded GLP-1 + nutritionist coaching, in-network for some plans
Best for: Compounded with nutrition coaching
Direct
Compounded 503A telehealth
Eden
Compounded semaglutide + tirzepatide, simple cash-pay
Best for: Streamlined cash-pay compounded access
Direct
Compounded 503A telehealth
FuturHealth
Compounded GLP-1 + AI-assisted personalization
Best for: AI-driven cash-pay model
Direct
Editorial selection. "Direct" links go to the company’s homepage — we are not yet an affiliate partner with them and earn no commission on those signups. "Affiliate" links route through our /go redirect with commission tracking.
Pair this with
Common questions
Why is the GLP-1 cash-price spread so wide?
Three distinct supply chains exist: compounded 503A (cheapest, $149-449/mo), manufacturer-direct vials (Lilly Direct $349-499/mo), and brand-name pen via telehealth ($499-1,349/mo). Each has different regulatory status, quality assurance, and insurance pathway. Spread comes from supply-chain choice, not just markup.
Which is the cheapest legal GLP-1 in 2026?
Compounded semaglutide from licensed 503A pharmacies starts at $199/mo (Push Health) — legal when prescribed for patient-specific need. Hims oral Wegovy at $149/mo is the cheapest brand-name path, but only on the introductory tier.
How often do these prices change?
We refresh this dataset quarterly from each provider's public rate card or intake screen. Compounded prices drop fastest (competitive race-to-bottom in 2026). Brand-name prices are sticky — Novo Nordisk and Eli Lilly hold list prices; movement comes from savings cards and direct-to-patient programs.
Is compounded GLP-1 the same as brand-name?
Same active molecule when sourced from USP-grade suppliers; different in FDA oversight (compounded is not FDA-approved as a finished product), inactive ingredients, and sterility-process variability between pharmacies. See our compounded-vs-brand pillar for the full safety + legality picture.
Methodology + raw data licensed CC-BY 4.0. We encourage other researchers + journalists to cite this dataset; attribution to Health Portal with a link back is the only requirement.